Galectin-3 in Septic and Non-septic Acute Kidney Injury

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-01-01

Study Completion Date

2023-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Acute kidney injury (AKI) is a common critical condition with high morbidity and mortality. The level of circulating Galectin-3 (Gal3) largely depends on renal function, so it is elevated in patients with AKI or CKD; elevated Gal3 also aggravates the progression of CKD after the onset of AKI. The proinflammatory and profibrotic properties of Gal3 may render it to be one of the key molecules mediating AKI, CKD, and cardiorenal syndrome. In this prospective observational study, the investigators will explore the differences of Gal3 levels among septic AKI, non-septic AKI, and non-AKI patients and its correlation with prognosis, inflammation, and disease severity in the ICU.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

NGAL and Renal Resistive Index in the Diagnosis and Prognosis of Sepsis-associated AKI

NCT05374759

Sepsis Acute Kidney Injury

COMPLETED

Serum Cysteine Rich Protein 61 and Cystatin C for Early Detection of Acute Kidney Injury in Patients With Heart Diseases

NCT05242705

Acute Kidney Injury

UNKNOWN

Serum and Urine Metabolome Studies in Patients With Acute Kidney Injury After Cardiac Surgery

NCT06245720

Cardiac Surgery Associated Acute Kidney Injury

ACTIVE_NOT_RECRUITING

Urinary NGAL Acute Kidney Injury After Stored Red Blood Cells Transfusion in Critically Ill Patients.

NCT03560921

Acute Kidney Injury Anemia

COMPLETED

Effect of CVVH on NGAL in Septic AKI

NCT02536027

Acute Kidney Injury

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Acute kidney injury (AKI) is a common critical condition with high morbidity and mortality. Not only can AKI cause death in the acute phase, but also can it be associated with the development of chronic kidney disease (CKD) or the progression of CKD. Galectins are members of a lectin family widely expressed in vertebrates, among which galectin-3 (Gal3) is the most studied one. The level of circulating Gal3 largely depends on renal function, so it is elevated in patients with AKI or CKD; elevated Gal3 also aggravates the progression of CKD after the onset of AKI. The proinflammatory and profibrotic properties of Gal3 may render it to be one of the key molecules mediating AKI, CKD, and cardiorenal syndrome. However, the mechanisms of AKI differ from different etiologies, and the process and extent of levels of Gal3 may be also different, so its predictive value in prognosis may vary in different types of AKI. In critically ill patients, AKI is a common complication of sepsis, and sepsis is the most common trigger of AKI. In this prospective observational study, the investigators will explore the differences of Gal3 levels among septic AKI, non-septic AKI, and non-AKI patients and its correlation with prognosis, inflammation, and disease severity in the ICU.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Kidney Injury Sepsis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

septic AKI: S-AKI

Septic patients with AKI

Standard Reagents, Whole Blood

Intervention Type DRUG

All patients receive standard treatment, only their blood and urine samples are needed

non-septic AKI: non-S AKI

Non-septic critically ill patients with AKI.

Standard Reagents, Whole Blood

Intervention Type DRUG

All patients receive standard treatment, only their blood and urine samples are needed

non-AKI Non-AKI

Critically ill patients without sepsis and AKI.

Standard Reagents, Whole Blood

Intervention Type DRUG

All patients receive standard treatment, only their blood and urine samples are needed

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Standard Reagents, Whole Blood

All patients receive standard treatment, only their blood and urine samples are needed

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Urine samples within 24 hours after ICU admission

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. 18 years old or more.
* 2\. The patient himself or his agent is able to provide informed consent and provide adequate information for the endpoint assessment.
* 3\. Renal function was stable before this onset, and there was no evidence of plasma creatinine rising by 0.3 mg/dL within 3 months of study entry and not receiving RRT.

Exclusion Criteria

* 1\. Age less 18 years old.
* 2\. There were previous acute kidney injury, kidney transplantation, chronic kidney disease, or with a glomerular filtration rate of less than 30 mL/min, or hepatorenal syndrome, or pregnancy.
* 3\. Patients with an expected survival time of less than 6 months.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No